Dr. Patrick Brunner, M.D.
Dermatology (Dermatology Physician)
1230 York Ave, The Rockefeller University Hospital
New York, NY 10065
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 173
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NY license 290252-01
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 173
- Services billed
- 372
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 69 | 59 |
| New patient office or other outpatient visit, 45-59 minutes | 41 | 41 |
| Destruction of precancer skin growth, 1 growth | 28 | 26 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 24 | 18 |
| Destruction of skin growth, 1-14 growths | 18 | 18 |
| Biopsy of related skin growth, first growth | 12 | 12 |
| Destruction of precancer skin growth, 2-14 growths | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in New York, NY | 67 |
| Triamcinolone Acetonide Other prescribers in New York, NY | 63 |
| Clobetasol Propionate Other prescribers in New York, NY | 52 |
| Fluocinonide Other prescribers in New York, NY | 33 |
| Minoxidil Other prescribers in New York, NY | 30 |
| Opzelura (ruxolitinib phosphate) | 24 |
| Taltz Autoinjector (ixekizumab) | 23 |
| Mometasone Furoate Other prescribers in New York, NY | 23 |
| Tacrolimus Other prescribers in New York, NY | 22 |
| Mupirocin Other prescribers in New York, NY | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 34 payments worth $42,597 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,211 |
|---|---|
| AbbVie Inc. | $8,794 |
| Immunocore Limited | $5,429 |
| Eli Lilly and Company | $4,800 |
| UCB SA | $3,000 |
| Pfizer Inc. | $2,704 |
| Incyte Corporation | $1,332 |
| Leo Pharma As | $1,066 |
| Consulting Fee | $33,868 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,800 |
| Honoraria | $2,552 |
| Food and Beverage | $732 |
| Travel and Lodging | $645 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 23, 2025 | Consulting Fee | $12,600 |
| AbbVie Inc. Jan 7, 2025 | Consulting Fee | $8,750 |
| Immunocore Limited Sep 25, 2025 | Consulting Fee | $5,370 |
| Eli Lilly and Company Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $4,000 |
| UCB SA Oct 24, 2025 | Consulting Fee | $3,000 |
| Pfizer Inc. Nov 11, 2025 | Honoraria | $2,552 |
| Incyte Corporation Dec 22, 2025 | Consulting Fee | $1,332 |
| Leo Pharma As Dec 15, 2025 | Consulting Fee | $1,066 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 17, 2025 | Consulting Fee | $900 |
| Almirall LLC Oct 7, 2025 | Consulting Fee | $850 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 22, 2025 | Consulting Fee | $1,332 |
| Leo Pharma As Dec 15, 2025 | Consulting Fee | $1,066 |
| Eli Lilly and Company Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $4,000 |
| Pfizer Inc. Nov 11, 2025 | Honoraria | $2,552 |
| UCB SA Oct 24, 2025 | Consulting Fee | $3,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 17, 2025 | Consulting Fee | $900 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging travel to Ridgefield, CT · in-kind | $168 |
| Almirall LLC Oct 7, 2025 | Consulting Fee | $850 |
| Eli Lilly and Company Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $800 |
| Immunocore Limited Sep 25, 2025 | Consulting Fee | $5,370 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 23, 2025 | Consulting Fee | $12,600 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 20, 2025 | Travel and Lodging travel to Ridgefield, CT · in-kind | $239 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 20, 2025 | Travel and Lodging travel to Ridgefield, CT · in-kind | $239 |
| AbbVie Inc. Jan 7, 2025 | Consulting Fee | $8,750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $106,346 in research payments for these studies, mostly to the institutions running them.
- A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie Inc. · Active, not recruiting · NCT06118411 - M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)
AbbVie Inc. - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.